Experience of living donor liver transplantation for hepatocellular carcinoma in the University of Hong Kong Hospital

Abstract

Aim: To describe the current practise of living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC), including the patient selection criteria, surgical techniques, management of small-for-size syndrome, postoperative complications, and the results of our units, in the Liver Transplant Centre of Queen Mary Hospital, Hong Kong, one of the high-volume centres for LDLT in Asia.

Methods: Our centre practises careful selection for HCC patients using the University of California, San Francisco (UCSF) criteria, supplemented by alpha-fetoprotein level and the model for end-stage liver disease score. Slight flexibility is offered to enthusiastic donors and recipients in LDLT while balancing the risks and benefits. We pioneered in using the extended right lobe graft and the novel hepatic venoplasty technique, which lessen the risk of hyperperfusion and small-for-size syndrome with improved overall recipient survival. Data were collected prospectively and presented as the mean values and ranges, or the number of patients in proportion of total patient population.

Results: Of our patients, 74.9% met the UCSF criteria, and 64.5% met the Milan criteria. A 5-year overall and disease-free survival rate of 78.9% and 76.3% were achieved.

Conclusion: LDLT is an ideal treatment for HCC in Hong Kong with regard to the critical organ shortage and high demand for transplantation. The current surgical techniques and post-transplant surveillance contribute to the positive outcome.

Keywords

Living donor liver transplantation / hepatocellular carcinoma / high volume centre / LDLT / HCC

References

[1] Yoshizumi T,Itoh S.Living donor liver transplantation for hepatocellular carcinoma within milan criteria in the present era.Anticancer Res2016;36:439-45

[2] Chen CL,Concejero AM.Why does living donor liver transplantation flourish in Asia?.Nat Rev Gastroenterol Hepatol2013;10:746-51

[3] Worldwide liver transplant from deceased donors 2019 (PMP). Available from: https://www.irodat.org/?p=database [Last accessed on 7 Jan 2022]

[4] Lo CM,Liu CL.Adult-to-adult living donor liver transplantation using extended right lobe grafts.Ann Surg1997;226:261-9; discussion 269-70 PMCID:PMC1191019

[5] Liver transplant centre. (2019). Available from: https://www8.ha.org.hk/qmh/patient_and_visitor/medical_services/liver_transplant_centre.aspx [Last accessed on 7 Jan 2022]

[6] Blok JJ,Putter H.Eurotransplant Liver Intestine Advisory CommitteeThe center effect in liver transplantation in the Eurotransplant region: a retrospective database analysis.Transpl Int2018;31:610-9

[7] Macomber CW,Santry H.Centre volume and resource consumption in liver transplantation.HPB (Oxford)2012;14:554-9 PMCID:PMC3406353

[8] Chan SC,Ng KK,Yong BH.Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein.Liver Transpl2011;17:115-21

[9] Fan ST,Liu CL.Technical refinement in adult-to-adult living donor liver transplantation using right lobe graft.Ann Surg2000;231:126-31 PMCID:PMC1420975

[10] Lo CM,Liu CL.Hepatic venoplasty in living-donor liver transplantation using right lobe graft with middle hepatic vein.Transplantation2003;75:358-60

[11] Fan ST,Yong BH. Living donor liver transplantation. World Scientific; 2011.

[12] She WH,Fung JY,Lo CM.Outcomes of right-lobe and left-lobe living-donor liver transplantations using small-for-size grafts.World J Gastroenterol2017;23:4270-7 PMCID:PMC5483501

[13] Lo CM,Liu CL.Minimum graft size for successful living donor liver transplantation.Transplantation1999;68:1112-6

[14] Kawasaki S,Matsunami H.Living related liver transplantation in adults.Ann Surg1998;227:269-74 PMCID:PMC1191245

[15] de Villa VH,Chen YS.Right lobe living donor liver transplantation-addressing the middle hepatic vein controversy.Ann Surg2003;238:275-82 PMCID:PMC1422691

[16] Ma KW,Chan ACY.Impact of small-for-size liver grafts on medium-term and long-term graft survival in living donor liver transplantation: a meta-analysis.World J Gastroenterol2019;25:5559-68 PMCID:PMC6767984

[17] Man K,Lo CM.Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression.Ann Surg2003;237:256-64 PMCID:PMC1522144

[18] Ito T,Yamamoto H.Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications.Transplantation2003;75:1313-7

[19] Wei WI,Ng RW.Microvascular reconstruction of the hepatic artery in live donor liver transplantation: experience across a decade.Arch Surg2004;139:304-7

[20] Dindo D,Clavien PA.Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.Ann Surg2004;240:205-13 PMCID:PMC1360123

[21] Arbuthnot P.Hepatitis B virus and hepatocellular carcinoma.Int J Exp Pathol2001;82:77-100 PMCID:PMC2517704

[22] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996;334:693-9

[23] Yao FY,Bass NM.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001;33:1394-403

[24] Ma KW,Fung JYY.Liver transplantation for hepatitis B virus-related hepatocellular carcinoma in Hong Kong.J Clin Transl Hepatol2018;6:283-8 PMCID:PMC6160307

[25] Lin C,Chen C.Living donor liver transplantation for hepatocellular carcinoma. In: Abdeldayem HM, editor. Updates in Liver Cancer. InTech; 2017.

[26] Mailey B,Khalili J.Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.Arch Surg2011;146:26-33

[27] Todo S,Tada M.Extending indication: role of living donor liver transplantation for hepatocellular carcinoma.Liver Transpl2007;13:S48-S54

[28] Zheng SS,Wu J.Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.Transplantation2008;85:1726-32

[29] Todo S.Japanese Study Group on Organ TransplantationLiving donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.Ann Surg2004;240:451-9; discussion 459-61 PMCID:PMC1356435

[30] Ng KK,Chan SC,Cheung TT.Liver transplantation for hepatocellular carcinoma: the Hong Kong experience.J Hepatobiliary Pancreat Sci2010;17:548-54

[31] Bhangui P,Vibert E.Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes?.Ann Surg2016;264:155-63

[32] Broelsch CE,Emond JC.Liver transplantation in children from living related donors. Surgical techniques and results.Ann Surg1991;214:428-37; discussion 437-9 PMCID:PMC1358542

[33] Hatano E,Yabe S.Hepatic artery thrombosis in living related liver transplantation.Transplantation1997;64:1443-6

[34] Sakamoto Y,Nakatsuka T.Rescue of liver grafts from hepatic artery occlusion in living-related liver transplantation.Br J Surg1999;86:886-9

[35] Goldstein MJ,Kapur S.Analysis of failure in living donor liver transplantation: differential outcomes in children and adults.World J Surg2003;27:356-64

[36] Millis JM,Brady LM.Primary living-donor liver transplantation at the University of Chicago: technical aspects of the first 104 recipients.Ann Surg2000;232:104-11 PMCID:PMC1421114

[37] Uchiyama H,Hiroshige S.Hepatic artery reconstruction in living-donor liver transplantation: a review of its techniques and complications.Surgery2002;131:S200-4

[38] McAlister VC,Renouf E,Kjaer MS.Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis.Am J Transplant2006;6:1578-85

[39] Randhawa PS,Demetris AJ.Tacrolimus (FK506)-associated renal pathology.Adv Anat Pathol1997;4:265-76 PMCID:PMC3092646

[40] Vivarelli M,Piscaglia F.Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.Liver Transpl2005;11:497-503

[41] Hojo M,Maluccio M.Cyclosporine induces cancer progression by a cell-autonomous mechanism.Nature1999;397:530-4

[42] Guba M,Steinbauer M.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.Nat Med2002;8:128-35

[43] Diekmann F.Practical considerations for the use of mTOR inhibitors.Transplant Res2015;4:5 PMCID:PMC4895281

[44] Liang W,Ling X.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.Liver Transpl2012;18:62-9

[45] Trotter J.Sirolimus in liver transplantation.Transplant Proc2003;35:S193-200

[46] McAlister VC,Malatjalian DA.Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.Liver Transpl2001;7:701-8

[47] Fung J.Management of chronic hepatitis B before and after liver transplantation.World J Hepatol2015;7:1421-6 PMCID:PMC4450205

[48] Lo CM,Lai CL.Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.Ann Surg2001;233:276-81 PMCID:PMC1421211

[49] Fung J,Cheung C.Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.Am J Gastroenterol2013;108:942-8

[50] Fung J,Chok K.Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years.Hepatology2017;66:1036-44

[51] Jr W. The first laparoscopic cholecystectomy.JSLS2001;5:89-94.

[52] Nguyen KT,Tsung A,Gamblin TC.Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal.Arch Surg2011;146:348-56

[53] Simillis C,Tekkis PP,Lovegrove R,Antoniou A.Laparoscopic versus open hepatic resections for benign and malignant neoplasms-a meta-analysis.Surgery2007;141:203-11

[54] Croome KP.Laparoscopic vs open hepatic resection for benign and malignant tumors: an updated meta-analysis.Arch Surg2010;145:1109-18

[55] Zhou YM,Zhao YF,Li B.Meta-analysis of laparoscopic versus open resection for hepatocellular carcinoma.Dig Dis Sci2011;56:1937-43

[56] Mirnezami R,Chandrakumaran K.Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis.HPB (Oxford)2011;13:295-308 PMCID:PMC3093641

[57] Mizuguchi T,Meguro M.Laparoscopic hepatectomy: a systematic review, meta-analysis, and power analysis.Surg Today2011;41:39-47

[58] Li N,Wu B.Surgical and oncologic outcomes following laparoscopic versus open liver resection for hepatocellular carcinoma: a meta-analysis.Hepatol Res2012;42:51-9

[59] Kim KH,Park KM.Comparison of open and laparoscopic live donor left lateral sectionectomy.Br J Surg2011;98:1302-8

[60] Kim SH,Kim YK.Pushing the frontiers of living donor right hepatectomy.World J Gastroenterol2014;20:18061-9 PMCID:PMC4277947

[61] Kim KH,Jung DH.Initial outcomes of pure laparoscopic living donor right hepatectomy in an experienced adult living donor liver transplant center.Transplantation2017;101:1106-10

[62] Wakabayashi G,Takahara T,Kitajima M.Standardization of basic skills for laparoscopic liver surgery towards laparoscopic donor hepatectomy.J Hepatobiliary Pancreat Surg2009;16:439-44

[63] Kim JH,Jang LC.Lateral approach liver hanging maneuver in laparoscopic anatomical liver resections.Surg Endosc2016;30:3611-7

[64] Pringle JH.V. Notes on the arrest of hepatic hemorrhage due to trauma.Ann Surg1908;48:541-9 PMCID:PMC1406963

[65] Ishizawa T,Kokudo N.Clinical application of indocyanine green-fluorescence imaging during hepatectomy.Hepatobiliary Surg Nutr2016;5:322-8 PMCID:PMC4960410

[66] Giulianotti PC,Angelini M.Robotics in general surgery: personal experience in a large community hospital.Arch Surg2003;138:777-84

[67] Choi GH,Kim SH.Robotic liver resection: technique and results of 30 consecutive procedures.Surg Endosc2012;26:2247-58

[68] Choi SH,Han DH.Laparoscopic liver resection using a rubber band retraction technique: usefulness and perioperative outcome in 100 consecutive cases.Surg Endosc2015;29:387-97

[69] Park JI,Kim HJ.Highlights of the third expert forum of Asia-pacific laparoscopic hepatectomy; endoscopic and laparoscopic surgeons of Asia (ELSA) visionary summit 2017.Ann Hepatobiliary Pancreat Surg2018;22:1-10 PMCID:PMC5845605

[70] Chen PD,Wu YM.Use of robotics in liver donor right hepatectomy.Hepatobiliary Surg Nutr2017;6:292-6 PMCID:PMC5673766

[71] Chen PD,Hu RH.Robotic liver donor right hepatectomy: a pure, minimally invasive approach.Liver Transpl2016;22:1509-18

[72] Zhu P,Ding zy.learning curve in robot-assisted laparoscopic liver resection.J Gastrointest Surg2019;23:1778-87

[73] Saito Y,Imura S.A learning curve for laparoscopic liver resection: an effective training system and standardization of technique.Transl Gastroenterol Hepatol2018;3:45 PMCID:PMC6088150

[74] Sapisochin G,Laurence JM.The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study.Hepatology2016;64:2077-88

[75] Suzuki M,Fujikawa T.Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.J Biol Chem2005;280:6409-15

[76] Fujikawa T,Ueda N.Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration.J Biol Chem2007;282:8741-8

[77] Tanaka Y,Tsutsumi H.Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.Hepatogastroenterology1999;46:2464-8

[78] Ikoma J,Ishihara T.Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.Hepatogastroenterology2002;49:235-8

[79] Chaiteerakij R,Addissie BD.Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.Liver Transpl2015;21:599-606 PMCID:PMC4490162

[80] Funaki NO,Seto SI,Kaido T.Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver.Hepatology1997;25:564-8

[81] Kobayashi M,Ikeda K.Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.Hepatol Res2011;41:1036-45

[82] Limaye AR,Soldevila-Pico C.Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.Hepatol Res2013;43:757-64 PMCID:PMC3622781

[83] Halazun KJ,Rana AA.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.Ann Surg2009;250:141-51

[84] Ito T,Ueda M.Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.Liver Transpl2007;13:1637-44

[85] Toyoda H,Osaki Y.Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.Clin Gastroenterol Hepatol2006;4:1528-36